I. Introduction to Chengda Biology
Chengda Bio is a biotechnology enterprise focusing on the research, development, production and sales of vaccines for human use. The company is located at Chengda Bio -20 18 to 20 19 in Shenyang, Liaoning Province, and its sales of rabies vaccine products for human use ranked first in the world for two consecutive years. The core products of Chengda Bio include rabies vaccine for human use and inactivated Japanese encephalitis vaccine. The company's human rabies vaccine is the only rabies vaccine that can be injected with Zagreb2- 1- 1 in China, and the company's inactivated Japanese encephalitis vaccine is the only domestic inactivated Japanese encephalitis vaccine. According to the prospectus, the revenues of Chengda Bio 20 18, 20 19 and 2020 are 13 respectively. The net profit was 620 million yuan, 698 million yuan and 96.5438+0.8 million yuan respectively.
Second, the vaccine business growth expectations
The company's core products include rabies vaccine for human use and inactivated Japanese encephalitis vaccine. The company's human rabies vaccine is the only human vaccine that can be injected with Zagreb 2- 1- 1 in China, and the company's inactivated Japanese encephalitis vaccine is the only domestic inactivated Japanese encephalitis vaccine in China. In August this year, Chengda and the top three shareholders Liaoning, Shaoguan, Gao Teng, SASAC, Liaoning, Xinyi and Guangxi made corresponding commitments respectively, and the CSRC made corresponding commitments on 20265438+.
After deducting the issuance expenses, the funds raised by Chengda Bio will be used for the first-phase construction project of human vaccine of Benxi Branch of Liaoning Chengda Bio-Co., Ltd., the intelligent workshop construction project of human vaccine of Liaoning Chengda Bio-Co., Ltd., the research and development project of human vaccine of Liaoning Chengda Bio-Co., Ltd. and the supplementary liquidity project.